Track NervGen Pharma Common stock's total assets ($90M) with charts, peers, and YoY trends.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
NervGen Pharma Common stock (NGEN) currently reports a total assets of $90M as of June 2026. That compares with $17M in the prior-year period — up 431.2% year over year. Use the charts on this page to explore NervGen Pharma Common stock's total assets history and peer comparisons.
NervGen Pharma Common stock's total assets increased from $17M to $90M — a 431.2% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.
NervGen Pharma Common stock reported $90M in total assets as of June 2026. That compares with $17M in the prior-year period — up 431.2% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.
Start with the current total assets of $90M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for NervGen Pharma Common stock, and consider following NGEN for alerts when major investors trade the stock.
NervGen Pharma Common stock is classified in the Healthcare sector. On total assets, it currently shows $90M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing NGEN with unrelated industries.